Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has entered an exclusive worldwide license and collaboration agreement with GlobeImmune to develop and market therapeutic vaccine products and other oral therapies to treat chronic hepatitis B virus (HBV) infection.
Subscribe to our email newsletter
According to the deal, Gilead will pay GlobeImmune an upfront payment and provide support for continued development of GlobeImmune’s HBV therapeutic vaccine programme through Phase 1a clinical trials.
GlobeImmune will also receive additional payments based on achievement of development programme, as well as royalties on future potential net sales.
The collaboration aims to create therapeutic vaccine products that have specific HBV DNA antigens cloned into S. cerevisiae (a species of yeast).
The combination of a therapeutic vaccine with oral suppressive antiviral therapy is expected to help increase surface antigen (HBsAg) loss with seroconversion, a marker of the resolution of chronic HBV infection.